Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site. # |apersy| Value | Market Access | Commercialisation ## Sitemaps - [XML Sitemap](https://www.apersy.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [News and insights](https://www.apersy.com/news-and-insights/) - News, insights and publications - [Not launching in Europe is not the solution. European access preparedness – growing opportunities and risk mitigation](https://www.apersy.com/2026/01/15/not-launching-in-europe-is-not-the-solution-european-access-preparedness-growing-opportunities-and-risk-mitigation/) - Not launching in Europe is not the solutionEuropean access preparedness – growing opportunities and risk mitigation Taking a look at the new global access and pricing strategy context Download the Market Access Checklist In today’s turbulent geopolitical dynamics, there are many more moving parts when it comes to pricing, reimbursement and market access. What are - [Starting 2025: Don't forget to look beyond the JCA](https://www.apersy.com/2025/01/06/reimbursement-2025/) - While we are certainly all on lookout for the first EU Joint Clinical Assessments (JCA), there are quite a few other access, financing, pricing and reimbursement news and changes to watch as 2025 starts... - [Precision medicine and complex care environments. Dynamics in market access and reimbursement.](https://www.apersy.com/2024/01/02/value-in-2023/) - The health technology space has never been that exciting… and challenging at the same time. Gene therapies, microbiome products, digital therapeutics - 2023 was full of exciting market entries from the emerging healthtech field. - [Biotech market access preparedness](https://www.apersy.com/2025/10/17/biotech-market-access-preparedness/) - In a world where pricing and access dynamics have just gotten more complex, the market potential of a health technology needs to be shaped early. Let's take a look at the framework and key elements of market access preparedness. - [What Investors Want You to Know About Regulatory and Market Access Strategies](https://www.apersy.com/2025/09/10/what-investors-want-you-to-know-about-regulatory-and-market-access-strategies/) - You are invited! Eurofins Medical Device Services is organising this extremely relevant webinar with their regulatory and device development expertise. Apersy is pleased to join them with the Market Access and reimbursement point of view. - [Exploring access and reimbursement of digital medical devices and AI-based SaMD at ISPOR Europe 2024](https://www.apersy.com/2024/11/28/exploring-access-and-reimbursement-of-digital-medical-devices-and-ai-based-samd-at-ispor-europe-2024/) - Download poster presentation and conference attendance: ISPOR Europe 2024, 17-20 November 2024, Barcelona Exploring access and reimbursement of digital medical devices and AI-based SaMD at ISPOR Europe 2024 Reimbursement of digital medical devices (DMD) in Europe remains challenging with few dedicated access pathways and tailored reimbursement schemes. To date, remote care and remote monitoring and - [Weighing the Costs: Reimbursement of Anti-Obesity Medicines in the US and Europe](https://www.apersy.com/2024/09/17/weighing-the-costs-reimbursement-of-anti-obesity-medicines-in-the-us-and-europe/) - With the global burden of obesity continuing to rise, the tension between established reimbursement rules, increased efficacy of new anti-obesity medicines and the need to tackle this population health issue is becoming more pronounced. Reimbursement policies for anti-obesity medications vary significantly by region and are driven by country-specific healthcare priorities, reimbursement policies and budget constraints, as well as clinical guidelines. - [The dynamics in diagnostic imaging tenders and funding](https://www.apersy.com/2024/05/20/the-dynamics-in-diagnostic-imaging-tenders-and-funding/) - Reimbursement, access, competition and purchasing are highly dynamic in the diagnostic imaging technology field. - [Uncertainties Surrounding the EU Joint Clinical Assessment: What do biotechs need to monitor](https://www.apersy.com/2024/09/13/uncertainties-surrounding-the-eu-joint-clinical-assessment-what-do-biotechs-need-to-monitor/) - With the implementation of the new EU Health Technology Assessment (HTA) Regulation just four months away, uncertainties remain. The most important ones we will look at in this short clip, before exploring strategies for success the next time. - [Nononsense EU JCA](https://www.apersy.com/2024/08/08/nononsense-eu-jca-1/) - No-nonsense EU HTA Introducing bit-sized no-nonsense insights about the EU HTA Regulation, Joint Clinical Assessment, Joint Scientific Consultations, etc etc. In a series of posts, there will be Q&A, process overviews, insights about preparedness, uncertainties and unknowns, as well as news as they happen in the continuing implementation phase. Got a question or query to - [June market access news recap](https://www.apersy.com/2022/07/04/june-market-access-news-recap/) - Three minutes to spare? Selected news from the last month. This time from NICE and the G-BA... - [Apersy's 1st anniversary](https://www.apersy.com/2024/01/03/apersys-1st-anniversary/) - I started with the vision to create independent market access services that can support health tech companies through the challenges of precision medicine, complex treatment regimens and care approaches that blur the boundaries between device, pharmaceuticals and digital. - [November Market Access news recap](https://www.apersy.com/2022/12/05/november-market-access-news-recap/) - November market access news recap For the November recap a few news snippets from the pharma and digital health world: RWE collection in Germany, the Hemgenix gene therapy, early value assessment in England as well as the dynamic French digital health policy landscape. ... as usual, three minutes of your time ... - [October Market Access news: HTA & pricing policy updates](https://www.apersy.com/2022/11/02/october-market-access-news/) - This news update has a bit of a theme: HTA and reimbursement policies. There are a few reforms and regulation changes on-going across European markets, not to forget the preparations for the joint European HTA efforts through the Joint Clinical Assessment. Take three minutes to get on top of the latest updates. - [France PLFSS 2023: Social security financing bill puts pressure on medicine pricing](https://www.apersy.com/2022/10/05/france-plfss-2023-social-security-financing-bill-puts-pressure-on-medicine-pricing/) - France PLFSS 2023: Social security financing bill puts pressure on medicine pricing The draft of the French social security financing law for the year to come (PLFSS 2023) includes a few proposals that could have an impact on innovative medicine pricing, including ATMPs and products eligible for the "European price", meaning products that have demonstrated - [August & September 2022 Market Access news recap](https://www.apersy.com/2022/10/05/august-september-2022-market-access-news-recap/) - After the summer break, let's quickly catch-up with selected August and September news from the access and reimbursement sphere.... - [July 2022 Market Access news recap](https://www.apersy.com/2022/08/06/july-2022-market-access-news-recap/) - Three minutes selected reimbursement and pricing news from July, including the latest updates on the reform of German AMNOG early benefit assessment & pricing process. - [Germany: Changes to innovative drug pricing and AMNOG ahead?](https://www.apersy.com/2022/07/11/germany-changes-to-innovative-drug-pricing-and-amnog-ahead/) - Germany: Changes to innovative drug pricing and AMNOG ahead A new reform act to address the GKV (statutory health insurance) budget gap is in the making in Germany, and medicines funding does not remain untouched, most importantly, the price setting rules for innovative medicines through the AMNOG price negotiations. The first draft of the GKV - [Apersy at the 11th Microbiome & Probiotic R&D & Business Collaboration Forum: Europe, Rotterdam, 23-24 May 2023](https://www.apersy.com/2023/06/05/microbiome-forum-attendance/) - Apersy puts focus on market access preparedness at the 11th Microbiome & Probiotic R&D & Business Collaboration Forum: Europe (Rotterdam, 23-24 May 2023). - [Announcement of UK IDAP Pilot for medical devices - What does it mean for reimbursement?](https://www.apersy.com/2023/09/26/announcement-of-uk-idap-pilot-for-medical-devices-what-does-it-mean-for-reimbursement/) - The Innovative Devices Access Pathway (IDAP) Pilot is a first step to providing a faster and supported route to regulatory approval, access and adoption of innovative devices. But what precisely does this mean ultimately for access and reimbursement? - [French PECAN reimbursement applications have started… It's not a DiGA copy-paste](https://www.apersy.com/2023/08/07/pecan-vs-diga/) - .... the fundamental differences in the French and German access paths for digital medical devices - [Microbiome-targeting medicines: Commercial launch is moving centre stage](https://www.apersy.com/2023/04/25/microbiome-targeting-medicines-commercial-launch-is-moving-centre-stage/) - While Europe still lags behind in terms of microbiome medicines approvals, in the UK, we have seen the first Health Technology Assessment (HTA) for microbiota medicines. Let's have a closer look... - [March 2023 Monthly Reading List](https://www.apersy.com/2023/04/06/march-2023-monthly-reading-list/) - March-2023-Market-Access-news-recap.-reading-list ....What we were reading in March.... Funding weight-loss treatments AI regulation and access pathways in the UK: New developers resources Medical cannabis prescribing clarified in Germany The 'Not cost-effective at zero price' conundrum NICE's new proportionate approach to health technology evaluation - [February 2023 Monthly Reading List](https://www.apersy.com/2023/03/06/february-2023-monthly-reading-list/) - Selected reads from recent press or publications in the disruptive value, commercial and reimbursement space. - [January 2023 Market Access Reading List](https://www.apersy.com/2023/02/13/january-2023-market-access-reading-list/) - Recent news and articles to think about value and evidence development. This month, the news recap comes as short reading lists. - [December 2022 Market Access news recap](https://www.apersy.com/2023/01/11/december-2022-market-access-news-recap/) - The monthy 3 minutes of selected bits of news: 62 seconds on DiPAs - digital care and nursing applications are launching in Germany Microbiome product Rebyota is now approved in the US - we are keenly watching out for access, uptake and reimbursement learnings... AIFA reimbursement committees merge Germany rare disease medicine Brineura to recevie ## Pages - [Home](https://www.apersy.com/) - Building the foundations of successful reimbursement & market access Disruptive Health Tech & Personalised Medicine Innovative Biotech Digital Medicines & Healthcare AI Microbiome products Market Access Checklist European Access Preparedness Download and free consultation To the Checklist Book consultation now Start shaping product value early Value Creation Value is being created by making appropriate scientific - [](https://www.apersy.com/check-list-download/) - European Market Access Checklist This checklist, derived from specialist knowledge of the European Health Technology Assessment (HTA) systems and pricing environments, is designed to help biotechs in Phase 1-2 to identify and close critical strategic knowledge gaps and related evidence gaps that can cause costly delays and suboptimal reimbursement. Your ability to execute this checklist - [](https://www.apersy.com/market-access-checklist-free-consultation/) - European access and reimbursement Market Access Checklist & Free Consultation Access preparedness starts now In today’s turbulent geopolitical dynamics, there are many more moving parts when it comes to pricing, reimbursement and market access. Strategic access and price considerations are getting more complex and need to be taken earlier in development. Fund raising, partnering and - [About Apersy](https://www.apersy.com/about-apersy/) - Apersy provide flexible support to bring the payer point of view to your development programme Extensive experience, unique expertise Seeing pricing and market access from all sides: experience working for different stakeholders CROs Investment management NGOs/think tanks Big pharma Biotech Start-ups & techtransfer However novel your product or particular your situation, weird and wonderful is - [Services](https://www.apersy.com/services/) - Expert Market Access strategy & evidence planning Value Creation Make the right scientific and commercial choices from the start of development based on solid insights and optimisation of a reimbursable product profile. Environment & market understanding Opportunity assessment Strategic positioning, asset strategy, early commercial planning Business model & portfolio Value to Price In the era - [manifest](https://www.apersy.com/manifest/) - WHAT IS VALUE CREATION STRATEGY? by Henrike Granzow Apersy’s expertise and approach to commercial strategy and market access is all about value and value creation. But what exactly is this illusive concept of value? And how and why do you leverage value to achieve optimal pricing, speedy reimbursement and patient access? And what precisely is - [11th Microbiome Forum poster: MAPF](https://www.apersy.com/11th-microbiome-forum-poster-mapf/) - poster presentation A Framework for Market Access Preparedness for microbiome-targeting therapies We presented our take on commercial strategy and access preparedness for microbiome therapies at the 11th Microbiome & Probiotic R&D & Business Collaboration Forum: Europe (Rotterdam, 23-24 May 2023). Download The poster got you interested? We specialise in new health technologies, disruptive medicines and - [Legal Notice & Terms of Use](https://www.apersy.com/legal/legal-notice-terms-of-use/) - Legal Terms and General terms and conditions of use In force on 04/01/2023 The purpose of these general conditions of use is to provide a legal framework for the terms and conditions of provision of the website http://www.apersy.com. Legal notice The website Apersy (hereinafter "the Site"), accessible at the address http://www.apersy.com is published Apersy SARL - [PRIVACY POLICY](https://www.apersy.com/legal/privacy-policy/) - Document updated on 04/01/2023 Apersy SARL ("Apersy"," "our", "we", "us" and "our") and our partners respect your privacy. We kindly ask you to read this privacy policy carefully to understand how your personal data is collected, processed and stored when you use the Apersy website, accessible via the url www.apersy.com. All personal data collected on - [Cookie Policy](https://www.apersy.com/legal/cookie-policy-eu/) - [Contact us](https://www.apersy.com/contact-us/) - Get in touch Contact contact@apersy.com +33 637 52 46 47 Contact Form - [Legal](https://www.apersy.com/legal/) - Legal Notice & Terms of use Cookie Policy Privacy Policy ## Categories - [Uncategorized](https://www.apersy.com/category/uncategorized/) ## Tags - [Germany](https://www.apersy.com/tag/germany/) - [AMNOG](https://www.apersy.com/tag/amnog/) - [Digital health](https://www.apersy.com/tag/digital-health/) - [France](https://www.apersy.com/tag/france/) - [microbiome](https://www.apersy.com/tag/microbiome/) - [NICE](https://www.apersy.com/tag/nice/) - [pricing](https://www.apersy.com/tag/pricing/) - [advanced therapies](https://www.apersy.com/tag/advanced-therapies/) - [Medical devices](https://www.apersy.com/tag/medical-devices/) - [Investment & Fundraising](https://www.apersy.com/tag/investment-fundraising/) - [Orphan medicines](https://www.apersy.com/tag/orphan-medicines/) - [Evidence Generation](https://www.apersy.com/tag/evidence-generation/) - [personalised therapies](https://www.apersy.com/tag/personalised-therapies/) - [complex care environment](https://www.apersy.com/tag/complex-care-environment/) - [UK](https://www.apersy.com/tag/uk/) - [Healthcare innovation](https://www.apersy.com/tag/healthcare-innovation/) - [market access](https://www.apersy.com/tag/market-access/) - [EUHTA](https://www.apersy.com/tag/euhta/) - [JCA](https://www.apersy.com/tag/jca/) - [EUHTAR](https://www.apersy.com/tag/euhtar/) - [HTA](https://www.apersy.com/tag/hta/) - [oncology](https://www.apersy.com/tag/oncology/) - [Europe](https://www.apersy.com/tag/europe/) - [Health Technology Assessment](https://www.apersy.com/tag/health-technology-assessment/) - [HTA Regulation](https://www.apersy.com/tag/hta-regulation/) - [Obesity Care](https://www.apersy.com/tag/obesity-care/) - [Medical weight loss](https://www.apersy.com/tag/medical-weight-loss/) - [GLP-1](https://www.apersy.com/tag/glp-1/) - [Anti-obesity drugs](https://www.apersy.com/tag/anti-obesity-drugs/) - [Pharma](https://www.apersy.com/tag/pharma/) - [AI](https://www.apersy.com/tag/ai/) - [Purchasing](https://www.apersy.com/tag/purchasing/) - [Medical Innovation](https://www.apersy.com/tag/medical-innovation/) - [AI in healthcare](https://www.apersy.com/tag/ai-in-healthcare/) - [HTAR](https://www.apersy.com/tag/htar/) - [Healthcare financing](https://www.apersy.com/tag/healthcare-financing/) - [biotech](https://www.apersy.com/tag/biotech/) - [access preparedness](https://www.apersy.com/tag/access-preparedness/) - [Payer thinking](https://www.apersy.com/tag/payer-thinking/)